Oric Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1B Trial of Oric-114 in Patients With Mutated Nsclc
Oric Pharmicals宣佈在針對突變非小細胞肺癌患者的Oric-114的1B期試驗中,三個擴展隊列中首批患者給藥
Oric Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1B Trial of Oric-114 in Patients With Mutated Nsclc
Oric Pharmicals宣佈在針對突變非小細胞肺癌患者的Oric-114的1B期試驗中,三個擴展隊列中首批患者給藥
使用瀏覽器的分享功能,分享給你的好友吧